Does Cymbalta cause apathy? (+3 factors)
By
Ivan Kahwa
Author bio
Mr Ivan Kahwa is a chemist and phytopharmaceutical scientist with expertise in chemistry, pharmacology, phytochemistry, and Nanobiotechnology. He writes and reviews content on these topics.
Mr Ivan Kahwa’s Highlights:
Guest Researcher at the University of Leipzig, Senior Research Fellow/Scientist, and Lecturer at the Department of Pharmacy, Faculty of Medicine, Mbarara University of Science and Technology.
Professional Experience:
Mr Ivan joined PHARMBIOTRAC as a research fellow/scientist during his master of science tenure. He contributed to the development of most of the phytopharmaceutical products in the project. Furthermore, he participated in carrying out the pharmacological activities of the developed products in laboratory animals such as mice and rats in order to develop proper doses hence leading to pre-clinical studies.
With the above relevant research experience, Ivan started to work with the University of Leipzig on collaborative projects with Mbarara University to develop the chemistry of Ugandan Medicinal plants and their pharmacological activities. This was coupled with several consultative positions by different German NGOs. Mr. Kahwa is also a supporting in the teaching and learning at the Departments of Pharmacy and Pharmaceutical Sciences, Faculty of Medicine, Mbarara University of Science and Technology.
With the increase in antimicrobial resistance globally, Ivan retooled his thinking towards developing new naturally derived antibiotic regimens from Ugandan propolis with the assistance of nanotechnology to improve their delivery to microbial cells. Kahwa has also published over 28 articles in peer-reviewed journals and he is currently reviewing for many journals.
Education:
2023-2027: PhD in Pharmaceutical Sciences (ongoing) with a focus on Pharmaceutical Microbiology and Nanobiology at Mbarara University of Science and Technology.
2022: 2Msc. in Pharmacognosy and Natural Medicine Science at Mbarara University of Science and Technology.
2018: Bachelor of Science (Chemistry) at Mbarara University of Science and Technology.
Publications:
▪ Iqbal, S., Jabeen, F., Kahwa, I., & Omara, T. 2023. Suberosin Alleviates Thiazolidinedione-Induced Cardiomyopathy in Diabetic Rats by Inhibiting Ferroptosis via Modulation of ACSL4-LPCAT3 and PI3K-AKT Signaling Pathways. Cardiovascular Toxicology. https://doi.org/10.1007/s12012-023-09804-7
▪ Gupta, A. K., Yadav, R., Sharma, S., Sawale, J., & Kahwa, I. 2023. Anti-ageing Activity and Antioxidant Activity of Methanol Extracts of Leaves and Flowers of Salvia officinalis and Rosmarinus officinalis. Journal of Young Pharmacists, 15(3), 448–455. https://doi.org/10.5530/jyp.2023.15.60
▪ Tolo, C.U., Kahwa, I., Nuwagira, U., Weisheit, A. and Ikiriza, H., 2023. Medicinal plants used in treatment of various diseases in the Rwenzori Region, Western Uganda. Ethnobotany Research and Applications, 25, pp.1-16.
https://ethnobotanyjournal.org/index.php/era/article/view/4683
▪ Kahwa, I., Ajayi, C.O., Yadav, R., Chauhan, N.S., Shah, K., Abdelgadir, A.A., Shegena, E.A., Daniel, S., Omara, T., Asiimwe, J.B. and Ikiriza, H., 2023. Pharmacognostic and phytochemical studies as an invaluable approach for correct identification of medicinal plants: The case of Artemisia vulgaris L. substituted for Artemisia annua L. in Western Uganda. TMR Integr Med, 7, p.e23004.
https://doi.org/10.53388/TMRIM202307004
▪ Nalimu, F., Oloro, J., Kahwa, I. and Ogwang, P.E., 2021. Review on the phytochemistry and toxicological profiles of Aloe vera and Aloe ferox. Future Journal of Pharmaceutical Sciences, 7, pp.1-21.
https://doi.org/10.1186/s43094-021-00296-2
▪ Elamin, O.H.S., Ali, M.A., Elgezuli, I.A.A., Bashir, M.A. and Kahwa, I., 2021. Diagnosis of pre-and post-treatment of echinococcus granulosus with counter current immune electrophoresis and bacterial co-agglutination. Journal of Microbiology and Infectious Diseases, 11(02), pp.88-94.
https://doi.org/10.5799/jmid.951600
Published book Chapter
▪ Kahwa, I., Ayesiga, I., Nakalema, S., Alinaiswe, R., Mbabazi, R. and Iqbal, S., 2023. Natural products in the management of onchocerciasis. In Natural Products in Vector-Borne Disease Management (pp. 63-80). Academic Press. Book Chapter.
https://doi.org/10.1016/B978-0-323-91942-5.00012-4
Submitted manuscripts Under Review:
▪ Comparison of the Wound Healing Activity of the Leaf and Leaf Ash Extracts of Vernonia amygdalina in Rats. Journal name: Clinical Phytoscience
▪ Ethnobotanical Survey of Medicinal plants used in the management of cancer in Uganda. Journal name: Journal of Herbal Medicine
▪ Ethnobotanical survey and phytochemical screening of medicinal plants used in treatment of epilepsy by PROMETRA-Uganda Traditional Health Practitioners in Mpigi District, Uganda. Journal name: Journal of Ethnopharmacology
Submitted book chapters under review
1.Book title: Algae as a Natural Solution for Water-Food-Energy Nexus, Section 4: Microalgae and cyanobacteria for food applications, Chapter 4.6: Safety, toxicological and allergenic aspects of using algae for food. Authors: Christine Kyarimpa, Tom Omute, Caroline K. Nakiguli, Alice V. Khanakwa4, Christopher Angiro, Ivan Kahwa, Fortunate Ahumuza, Timothy Omara*. Publisher: Springer Nature Singapore Pte Ltd. 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore.
2.Book title: Nutraceuticals Inspiring the Contemporary Therapy for Lifestyle Diseases. Chapter: Nutraceutical applications of Seaweeds and their Phytocompounds in Nutrition and Treatment of Diseases. Authors: Ivan Kahwa, Timothy Omara , Innocent Ayesiga , Gael Noel Neh Neba Ambe , Zehbanaz Javidbhai Panwala , Rachel Mbabazi , Shabnoor Iqbal , Christine Kyarimpa , Christine Betty Nagawa , Kamal Shah ,Nagendra Singh Chauhan* Publisher: CRC Press
You can view my works on the following professional sites:
Research Gate: https://www.researchgate.net/profile/Ivan-Kahwa
Google Scholar: https://scholar.google.com/citations?user=tOwrvqoAAAAJ&hl=en
ORCID: https://orcid.org/0000-0002-6440-3437
Linkedin: https://de.linkedin.com/in/ivan-kahwa-865450159
In this article, we will discuss whether Cymbalta causes apathy. We will also discuss the factors that may increase the risk of Cymbalta-induced apathy. Additionally, we will discuss the management tips for apathy and the alternatives to Cymbalta if it causes apathy.
Does Cymbalta cause apathy?
Cymbalta may rarely cause apathy. While instances of apathy as a side effect are infrequent, studies indicate that Cymbalta demonstrates efficacy in addressing and managing apathetic symptoms related to conditions such as depression and anxiety.
Cymbalta is an antidepressant medication, that is employed in the management of various health conditions such as depression, anxiety, fibromyalgia, and chronic pain. It reduces the sadness and apathy associated with depression by increasing the levels of serotonin and norepinephrine in the brain (1).
While it is usually a well-tolerated medication, it may cause certain side effects in some individuals such as nausea, agitation, irritability, and dizziness (1).
What does research suggest?
While there is limited research specifically focused on the apathy caused by Cymbalta, available studies suggest that Cymbalta demonstrates effectiveness in managing apathy associated with various mental disorders such as depression and anxiety.
A research study reported that Cymbalta effectively managed apathy and sadness associated with depression in 31% of patients undergoing treatment with this medication (4).
In another study examining the tolerability of Cymbalta in patients with depression and Parkinson’s disease, the findings revealed that Cymbalta was effective in addressing symptoms, including apathy linked to depression. Moreover, the medication was well-tolerated by the participants in the study (2).
Cymbalta may induce apathy when used concurrently with other antidepressants, as evidenced by a research study reporting that a patient experienced symptoms of apathy after using Cymbalta concurrently with Lexapro and Remeron (3).
It is crucial to note that this observed side effect may be associated with the interaction of Cymbalta with other medications, rather than Cymbalta alone.
What factors can increase the risk of Cymbalta-induced apathy?
While the incidence of apathy induced by Cymbalta is low, it may cause apathy in some individuals with underlying risk factors such as:
Individual sensitivity: Individuals vary in their response to medications due to genetic, metabolic, and physiological differences. Some individuals may be more sensitive to the effects of Cymbalta, including potential side effects like apathy.
Concurrent medications: Cymbalta may interact with other medications, potentially amplifying or mitigating its effects. Concurrent use of certain medications, especially other antidepressants or drugs affecting the central nervous system, can influence the risk and severity of side effects.
Pre-existing medical conditions: Apathy may manifest in patients with pre-existing mental health conditions, such as depression or anxiety, and, while it may be related to these disorders, it is not directly associated with the use of Cymbalta.
Individuals with these underlying conditions may exhibit heightened susceptibility to specific side effects of Cymbalta, including apathy
What to do if Cymbalta causes apathy?
Cymbalta can rarely cause apathy as a side effect. However, if you experience this side effect, you must communicate with your healthcare provider right away. Apathy can have a significant impact on your well-being and daily life, so addressing it early is crucial for effective management.
Your healthcare provider will be able to evaluate the severity of your symptoms and explore appropriate adjustments to your treatment plan. This may include changes to your medication dosage, alternative medications, or complementary therapies.
It’s important to note that apathy can sometimes be influenced by factors other than medication, such as stress, lifestyle factors, or the presence of other medical conditions. Your healthcare provider may assess these potential contributors as well.
Having an open discussion about your experiences will enable your healthcare team to tailor your treatment and provide the necessary support for your mental health.
What are the alternatives to Cymbalta if it causes apathy?
If Cymbalta causes apathy or undesirable side effects, your healthcare provider may consider alternative medications. Some alternative options that your healthcare provider may consider include (4,5):
- desvenlafaxine
- venlafaxine
- bupropion
- phenelzine
- amitriptyline
Your healthcare provider will evaluate your symptoms and medical history before suggesting an alternative treatment. It’s crucial to work together with your healthcare team to develop a treatment plan that effectively addresses your symptoms with minimal side effects.
Never modify your medication routine without first consulting your healthcare provider as it may worsen your symptoms.
Was this helpful?
References
1.-
Dhaliwal JS, Spurling BC, Molla M. Duloxetine. 2023 May 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 31747213. https://pubmed.ncbi.nlm.nih.gov/31747213/
2.-
Takahashi M, Tabu H, Ozaki A, Hamano T, Takeshima T; REBORN study group. Antidepressants for Depression, Apathy, and Gait Instability in Parkinson’s Disease: A Multicenter Randomized Study. Intern Med. 2019 Feb 1;58(3):361-368. doi: 10.2169/internalmedicine.1359-18. Epub 2018 Aug 24. PMID: 30146591; PMCID: PMC6395136. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395136/
3.-
Kim HG, Koo BH, Lee SW, Cheon EJ. Apathy syndrome in a patient previously treated with selective serotonin reuptake inhibitors for depression. Yeungnam Univ J Med. 2019 Sep;36(3):249-253. doi: 10.12701/yujm.2019.00150. Epub 2019 Mar 15. PMID: 31620640; PMCID: PMC6784646. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784646/
4.-
Alvarez-Mon MA, García-Montero C, Fraile-Martinez O, Quintero J, Fernandez-Rojo S, Mora F, Gutiérrez-Rojas L, Molina-Ruiz RM, Lahera G, Álvarez-Mon M, Ortega MA. Current Opinions about the Use of Duloxetine: Results from a Survey Aimed at Psychiatrists. Brain Sci. 2023 Feb 15;13(2):333. doi: 10.3390/brainsci13020333. PMID: 36831876; PMCID: PMC9953910. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953910/
5.-
Corcoran C, Wong ML, O’Keane V. Bupropion in the management of apathy. J Psychopharmacol. 2004 Mar;18(1):133-5. doi: 10.1177/0269881104043284. PMID: 15107198. https://pubmed.ncbi.nlm.nih.gov/15107198/
Find a supportive therapist who can help with Depression.
Discover the convenience of BetterHelp, an online therapy platform connecting you with licensed and accredited therapists specialized in addressing issues such as depression, anxiety, relationships, and more. Complete the assessment and find your ideal therapist within just 48 hours.
AskYourPharm is user-supported. We may earn a commission if you sign up for BetterHelp’s services after clicking through from this site
